Business ❯ Pharmaceuticals ❯ Biotechnology

Drug Development

Obesity Treatments Clinical Trials Clinical Research Molecular Glue Degraders Acquisitions Prostate Cancer Therapeutics Collaboration Bispecific Antibodies RNA Technology Blood Coagulation Treatments Monte Rosa Therapeutics Efzofitimod Artificial Intelligence Rare Diseases Collaboration Agreements Cystic Fibrosis Treatments FDA Regulations Generative AI Autoimmune Diseases Oral Biologics Weight Loss Drugs Licensing Agreements CAR T-cell Therapy Market Access Myelofibrosis Evotec SE Regulatory Affairs

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

The pact taps an AI-enabled gut-on-a-chip platform to turn injectable peptides into pills in a crowded GLP-1 market.

Viking Therapeutics' Obesity Drug Moves Into Phase 3 as Investors Weigh Upside

Lilly, Repertoire Strike Up-to-$1.93 Billion Autoimmune Drug Pact

Insilico, Qilu Strike Near-$120 Million AI Drug Discovery Pact for Cardiometabolic Therapies

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

Telix Securities Suit Advances as Investor Firms Push Lead-Plaintiff Bids Before Jan. 9 Deadline

Vertex Tops Q3 Estimates on CF Franchise as New Drugs Miss and Outlook Edges Higher

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

Rani Therapeutics and Chugai Sign Oral Biologics Collaboration Worth Up to $1.085 Billion

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet

CSL Secures VarmX Acquisition Option, Funding Phase 3 of Factor Xa Reversal Drug

Vertex Halts VX-993 Acute Pain Program After Phase 2 Trial Failure

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy

Cidara’s CD388 Antiviral Achieves Up to 76% Flu Protection in Phase 2b Trial

Pfizer Secures $6 Billion Licensing Deal for Chinese Cancer Drug SSGJ-707